The U.S. Food & Drug Administration (FDA) has approved all four dosage strengths of the new Sular® formulation of Sciele Pharma, Inc.

Sciele Pharma, Inc. specializes in sales, marketing and development of branded prescription products focused on Cardiovascular/Metabolic, Women's Health and Pediatrics. The U.S. Food & Drug Administration (FDA) has approved all four dosage strengths of the new Sular® formulation.

The new Sular formulation, which utilizes SkyePharma's patented GEOMATRIX™ technology, provides a lower dose of Sular for each of its current doses. The Company expects to launch the new Sular formulation during the first quarter of 2008.